WO2024089622 - ADGRE2 CHIMERIC RECEPTOR NK CELL COMPOSITIONS AND METHODS OF USE
National phase entry:
Publication Number
WO/2024/089622
Publication Date
02.05.2024
International Application No.
PCT/IB2023/060769
International Filing Date
25.10.2023
Title **
[English]
ADGRE2 CHIMERIC RECEPTOR NK CELL COMPOSITIONS AND METHODS OF USE
[French]
COMPOSITIONS DE CELLULES NK DU RÉCEPTEUR CHIMÉRIQUE ADGRE2 ET MÉTHODES D'UTILISATION
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
GAVIN, James
CURLEY, Michael
CAO, Lan
Priority Data
63/380,896
25.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3772 | |
| EPO | Filing, Examination, Granting | 39198 | |
| Japan | Filing, Examination, Granting | 3510 | |
| South Korea | Filing, Examination, Granting | 4822 | |
| USA | Filing, Examination, Granting | 20340 |
Total:
71,642
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.[French]
La présente demande concerne des cellules tueuses naturelles (CB-NK) dérivées du sang de cordon modifiées pour exprimer des récepteurs chimériques qui ciblent l'ADGRE2. La demande concerne également des compositions pharmaceutiques, des kits et des méthodes de traitement du cancer.